Markets

SeaStar Medical Announces FDA Determines QUELIMMUNE Pediatric SAVE Registry Has Fulfilled Post-Approval Study Requirements

Nov 3, 2026 · 08:22 AM ET· updated 2h ago

SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today

Why It Matters

SeaStar Medical finished a study the government asked them to do. This shows their medicine is working the way it should for kids.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ICU2.47

+0.28 (+12.79%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.